NASDAQ
HRMY
Last Price
US $34.81
KEY FIGURES
MKT CAP
$2.0B
EPS
TTM
$2.52
PEG
TTM
-
P/E
TTM
13.82x
P/S
TTM
2.24x
YIELD
0.00%
GROWTH
Revenue Y/Y
40.30%
(FY vs FY)
EBITDA Y/Y
Cash Flow (DCF)
Fair Value
Market $34.81
—
Default assumptions
EBITDA Multiple
Fair Value
Market $34.81
14.16%
Default assumptions
Valuation
Financial
Performance
Financial stability - Cash flow debt coverage.
Harmony Biosciences Holdings, Inc. cash flow to debt ratio of 145.34% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Financial stability - Healthy cash flow growth.
Harmony Biosciences Holdings, Inc.'s free cash flow has increased 59.09% from $218.67M last year to $347.89M, signaling increasing performance
Financial stability - Healthy debt to equity ratio.
Harmony Biosciences Holdings, Inc.'s debt to equity ratio is 0.23, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.
Financial stability - Healthy debt to equity ratio development.
Harmony Biosciences Holdings, Inc.'s debt has decreased relative to shareholder equity from 0.28 last year to 0.23 today, signaling strengthened financials
Financial stability - Net debt/EBITDA.
Harmony Biosciences Holdings, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability
Financial stability - ICR.
Harmony Biosciences Holdings, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Harmony Biosciences Holdings, Inc.'s profit margin has decreased (-20.44%) in the last year from 20.36% to 16.20%, signaling decreasing performance
Financial stability - Short term assets vs short term liabilities.
Harmony Biosciences Holdings, Inc.'s short-term assets of $907.01M exceed its short-term liabilities of $252.13M
Increasing performance - ROA.
Harmony Biosciences Holdings, Inc.'s return on assets of 11.45% is higher than the 5.00% threshold, indicating efficient asset utilization
Increasing performance - Absolute return on equity.
Harmony Biosciences Holdings, Inc.'s return on equity of 17.19%, is higher than 15.00%, indicating good performance
Increasing performance - Earnings quality.
Harmony Biosciences Holdings, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Increasing performance - Earnings stability.
Harmony Biosciences Holdings, Inc. had positive net income in 5.00 out of 5 years, indicating stable and consistent earnings
Increasing performance - Free cash flow.
Harmony Biosciences Holdings, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Increasing performance - FCF yield.
Harmony Biosciences Holdings, Inc. has a free cash flow yield of 17.26%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Increasing performance - Healthy earnings growth.
Harmony Biosciences Holdings, Inc.'s yearly earnings has increased 9.07% since last year from $145.49M to $158.69M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Harmony Biosciences Holdings, Inc.'s yearly revenue has increased 21.51% since last year from $714.73M to $868.45M, signaling increasing performance
Increasing performance - ROIC.
ROIC 12.50% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Increasing performance - 3-year revenue CAGR.
Harmony Biosciences Holdings, Inc.'s 3-year revenue CAGR of 25.64% is positive, indicating growing revenue over the past 3 years
Increasing performance - Revenue consistency.
Harmony Biosciences Holdings, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Increasing performance - ROE consistency.
Harmony Biosciences Holdings, Inc. had positive ROE in 5.00 out of 5 years, indicating consistent and reliable returns on equity
Overvalued - DCF valuation.
Harmony Biosciences Holdings, Inc. has insufficient data to evaluate this check.
Undervalued - Earnings yield.
Harmony Biosciences Holdings, Inc. has an earnings yield of 7.23%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
Undervalued - EBITDA valuation.
Harmony Biosciences Holdings, Inc. is undervalued relative to its fair value price of 39.74 based on EBITDA multiple model
Undervalued - EV/EBITDA.
Harmony Biosciences Holdings, Inc. has an EV/EBITDA ratio of 5.89x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
Overvalued - PEG ratio value.
Harmony Biosciences Holdings, Inc. has no meaningful EPS growth rate; PEG ratio cannot be computed.
Undervalued - P/B ratio.
Harmony Biosciences Holdings, Inc. has a price-to-book ratio of 2.21x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Undervalued - P/S ratio.
Harmony Biosciences Holdings, Inc. has a price-to-sales ratio of 2.24x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue
Profit margin
Current Ratio
Capital Returns
17.19%
Return on equity
ROIC: 12.50%
Valuation History
14.6X
Price to Earnings
EV/EBITDA: 7.5X
Cash flow
Profit margin
178.84%
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
EARNINGS FV (GRAHAM)
Fair Value
Market $34.81
120.11%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.